-
Something wrong with this record ?
Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma
M. Pásek, E. Marques, J. Švec, P. Arenberger, M. Arenbergerová
Language English Country England, Great Britain
Document type Letter, Observational Study
PubMed
38847436
DOI
10.1111/ijd.17285
Knihovny.cz E-resources
- MeSH
- Quinolines * therapeutic use administration & dosage adverse effects MeSH
- Adult MeSH
- Phenylurea Compounds * administration & dosage MeSH
- Antibodies, Monoclonal, Humanized * adverse effects therapeutic use administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Melanoma * drug therapy secondary pathology MeSH
- Skin Neoplasms * drug therapy pathology MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Letter MeSH
- Observational Study MeSH
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019160
- 003
- CZ-PrNML
- 005
- 20241024111721.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/ijd.17285 $2 doi
- 035 __
- $a (PubMed)38847436
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pásek, Marek $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0009000008758332
- 245 10
- $a Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma / $c M. Pásek, E. Marques, J. Švec, P. Arenberger, M. Arenbergerová
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a melanom $x farmakoterapie $x sekundární $x patologie $7 D008545
- 650 12
- $a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $x aplikace a dávkování $7 D061067
- 650 12
- $a fenylmočovinové sloučeniny $x aplikace a dávkování $7 D010671
- 650 12
- $a chinoliny $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D011804
- 650 12
- $a nádory kůže $x farmakoterapie $x patologie $7 D012878
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a dospělí $7 D000328
- 655 _2
- $a dopisy $7 D016422
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Marques, Emanuel $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000314516115
- 700 1_
- $a Švec, Jiří $u Department of Oncology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000347019625 $7 xx0254905
- 700 1_
- $a Arenberger, Petr $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000248005877 $7 nlk19990072992
- 700 1_
- $a Arenbergerová, Monika $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University, and Královské Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000279199619 $7 xx0074761
- 773 0_
- $w MED00009891 $t International journal of dermatology $x 1365-4632 $g Roč. 63, č. 9 (2024), s. e219-e220
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38847436 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111715 $b ABA008
- 999 __
- $a ok $b bmc $g 2201784 $s 1231133
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 63 $c 9 $d e219-e220 $e 20240607 $i 1365-4632 $m International journal of dermatology $n Int J Dermatol $x MED00009891
- LZP __
- $a Pubmed-20241015